GILD
GILEAD SCIENCES, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$153.07
−2.00%Year over year
Reported trailing growth
- Revenue
- +5.5%
- EBITDA
- -87.8%
- EBIT
- —
- EPS
- —
- Free cash flow
- +40.9%
- Operating cash flow
- +37.3%
Forward estimates
Based on analyst estimates
- Revenue
- +4.9%
- EBITDA
- +1281.8%
- EPS
- +464.9%
Three-year CAGR
- Revenue
- +2.6%
- EBITDA
- +15.3%
- EBIT
- +16.9%
- Net income
- +22.8%
- EPS
- +23.2%
- Free cash flow
- +4.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026